Associated Papers
Pharmacogenetics of First-Line Antitubercular Drugs: An Update.
Manca A et al.
Therapeutic Drug Monitoring, 2026
Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.
Verma S et al.
Drug Discovery Today, 2026
Pharmacogenomic heterogeneity of N-acetyltransferase 2: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review.
Thomas L et al.
Annals of Medicine, 2025
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.
Eadon MT et al.
Clinical Pharmacology and Therapeutics, 2025
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.
Naderi N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
Residue Variations in Human N‑Acetyltransferase 2 Enzyme Alleles: From Rapid to Slow Acetylation.
Veldman W et al.
Acs Omega, 2025
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort.
Schiuma M et al.
International Journal of Molecular Sciences, 2025
Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid.
Taylor J et al.
Southern African Journal of Hiv Medicine, 2025
Differential distribution of NAT2 polymorphisms and NAT2 acetylator phenotypes among indigenous populations of the Brazilian Amazon.
Perini JA et al.
Pharmacogenetics and Genomics, 2024
Determination of NAT2 Genotypes in a Cohort of Patients with Suspected TB in the State of Rio de Janeiro.
Dutra CA et al.
Pharmaceutics, 2024
A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
Verma R et al.
American Journal of Respiratory and Critical Care Medicine, 2024
N-acetyltransferase Gene Variants Involved in Pediatric Idiosyncratic Drug-Induced Liver Injury.
Alés-Palmer ML et al.
Biomedicines, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients.
Thomas L et al.
Expert Review of Clinical Pharmacology, 2024
Towards pharmacogenomics-guided tuberculosis (TB) therapy: N-acetyltransferase-2 genotypes among TB-infected Kenyans of mixed ethnicity.
Njagi LN et al.
Bmc Medical Genomics, 2024
Direct Comparative Analysis of a Pharmacogenomics Panel with PacBio Hifi® Long-Read and Illumina Short-Read Sequencing.
Barthélémy D et al.
Journal of Personalized Medicine, 2023
A case-control study in NAT2 gene polymorphism studies in patients diagnosed with acute myeloid leukemia.
Farasani A
Acta Biochimica Polonica, 2023
A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing.
Verma R et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Identification of PCSK9-like human gene knockouts using metabolomics, proteomics, and whole-genome sequencing in a consanguineous population.
Belkadi A et al.
Cell Genomics, 2023
Human N-acetyltransferase 2 (NAT2) gene variability in Brazilian populations from different geographical areas.
Lopes MQP et al.
Frontiers in Pharmacology, 2023
Genetic susceptibility of bladder cancer in the Lebanese population.
Kourie HR et al.
Bmc Medical Genomics, 2022
Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
van Rensburg R et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2022
Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.
Zyryanov SK et al.
Biomedicines, 2022
N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population.
Chorfi L et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2022
Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.
El-Jaick KB et al.
Memorias Do Instituto Oswaldo Cruz, 2022
A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
Verma R et al.
American Journal of Respiratory and Critical Care Medicine, 2021
Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients.
Levano KS et al.
Molecular Genetics & Genomic Medicine, 2021
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.
Hein DW et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
Functional Characterization of the Effects of N-acetyltransferase 2 Alleles on N-acetylation of Eight Drugs and Worldwide Distribution of Substrate-Specific Diversity.
Fukunaga K et al.
Frontiers in Genetics, 2021
Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer.
Rendo V et al.
Scientific Reports, 2020
Study on Genotyping Polymorphism and Sequencing of N-Acetyltransferase 2 (NAT2) among Al-Ahsa Population.
Zahra MA et al.
Biomed Research International, 2020
Genotype-Guided Hydralazine Therapy.
Collins KS et al.
American Journal of Nephrology, 2020
Genotype-Environment Interaction Analysis of NQO1, CYP2E1, and NAT2 Polymorphisms and the Risk of Childhood Acute Lymphoblastic Leukemia: A Report From the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia.
Medina-Sanson A et al.
Frontiers in Oncology, 2020
Mitochondrial DNA Variants in Patients with Liver Injury Due to Anti-Tuberculosis Drugs.
Lee LN et al.
Journal of Clinical Medicine, 2019
Role of the human N-acetyltransferase 2 genetic polymorphism in metabolism and genotoxicity of 4, 4'-methylenedianiline.
Salazar-González RA et al.
Archives of Toxicology, 2019
N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians.
Kotila OA et al.
Pharmacogenetics and Genomics, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers.
Jarrar YB et al.
The Libyan Journal of Medicine, 2018
Population genetic difference of pharmacogenomic VIP gene variants in the Lisu population from Yunnan Province.
Zhang C et al.
Medicine, 2018
Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia.
Hernández-González O et al.
Leukemia & Lymphoma, 2018
N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.
Aklillu E et al.
European Journal of Clinical Pharmacology, 2018
Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.
Dompreh A et al.
Antimicrobial Agents and Chemotherapy, 2018
NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris.
Dursun R et al.
Biomed Research International, 2018
Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity.
Chamorro JG et al.
Pharmacogenetics and Genomics, 2017
Distribution and Role of N-acetyltransferase 2 Genetic Polymorphisms in Bladder Cancer Risk in a Lebanese Population
Nasr R et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2017
Arylamine N-acetyltransferase 2 gene polymorphism in an Algerian population.
Chelouti H et al.
Annals of Human Biology, 2017
Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM et al.
Annals of Human Genetics, 2017